title: [Outcomes of patients with small bowel carcinoma treated with appropriate chemotherapy selected on the basis of genetic analysis findings].
abstract: Small bowel carcinoma is a rare tumor, for which a standardized chemotherapy regimen has not yet been established. Further, this tumor may belong to the group of Lynch syndrome-associated tumors, which are resistant to 5-fluorouracil (5-FU) -based chemotherapy. We investigated mismatch repair protein expression and K-ras gene mutation status in 8 patients with aggressive small bowel carcinoma and determined the chemotherapy regimen used in these patients. Immunohistochemical staining indicated normal mismatch repair protein expression in all surgical specimens. Of 8 patients, 4( 50%) had K-ras codon 12 mutations. Because small bowel carcinoma is not significantly associated with Lynch syndrome, 5-FU-based chemotherapy would be appropriate for the treatment of these patients. The prevalence of K-ras codon 12 mutations was relatively similar to that in patients with sporadic colorectal carcinoma, and the usefulness of anti- epidermal growth factor receptor (EGFR) antibody for the treatment of small bowel carcinoma should be evaluated in the future.
authors.affiliation: Dept. of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University.
authors.forename: Okihide
authors.initials: O
authors.lastname: Suzuki
authors.forename: Keiichiro
authors.initials: K
authors.lastname: Ishibashi
authors.forename: Hideko
authors.initials: H
authors.lastname: Imaizumi
authors.forename: Kunihiko
authors.initials: K
authors.lastname: Amano
authors.forename: Satoshi
authors.initials: S
authors.lastname: Hatano
authors.forename: Takeaki
authors.initials: T
authors.lastname: Matsuzawa
authors.forename: Tomohiko
authors.initials: T
authors.lastname: Ogita
authors.forename: Koki
authors.initials: K
authors.lastname: Kuwabara
authors.forename: Jun
authors.initials: J
authors.lastname: Sobajima
authors.forename: Toru
authors.initials: T
authors.lastname: Ishiguro
authors.forename: Morihiro
authors.initials: M
authors.lastname: Higashi
authors.forename: Minoru
authors.initials: M
authors.lastname: Fukuchi
authors.forename: Keisuke
authors.initials: K
authors.lastname: Kumamoto
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Baba
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Kumagai
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Tsuji
authors.forename: Junichi
authors.initials: J
authors.lastname: Tamaru
authors.forename: Erito
authors.initials: E
authors.lastname: Mochiki
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Ishida
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003062:Codon / Q000235:genetics; D005260:Female; D006801:Humans; D007078:Ileal Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D007580:Jejunal Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009154:Mutation; D011518:Proto-Oncogene Proteins / Q000235:genetics; D016283:Proto-Oncogene Proteins p21(ras); D016896:Treatment Outcome; D018631:ras Proteins / Q000235:genetics
chemical_list: D003062:Codon; C117307:KRAS protein, human; D011518:Proto-Oncogene Proteins; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins